U.S. Markets open in 3 hrs 8 mins

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
46.26-2.97 (-6.03%)
At close: 04:00PM EST
46.70 +0.44 (+0.95%)
Pre-Market: 04:46AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close49.23
Bid0.00 x 800
Ask47.91 x 900
Day's Range43.98 - 46.37
52 Week Range43.64 - 93.94
Avg. Volume488,365
Market Cap5.606B
Beta (5Y Monthly)1.88
PE Ratio (TTM)94.02
EPS (TTM)0.49
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est86.60
  • GlobeNewswire

    Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV:PGRN)

    — Companies to advance clinical development of DNL593 as a brain-penetrant progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN) — SOUTH SAN FRANCISCO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that its strategic partner Takeda Pharmaceutical Company Limite

  • Insider Monkey

    Should You Now Liquidate Your Denali Therapeutics (DNLI) Position?

    Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. A return of 1.18% was delivered by the fund’s institutional shares for the third quarter of 2021, outperforming both its S&P 500 and Russell 3000 Health Care benchmarks that […]

  • Zacks

    Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss

    Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.